Fig. 5

MS-275 enhances the efficacy of immunotherapies targeting the NKG2A–HLA-E axis in vivo. A Schematic diagram of the in vivo combination treatment in TT150630-bearing mice. The mice were treated with MS-275 (daily × 14 days, i.p.). MS-275 was administered for two days before being combined with intratumoral NK-92MI injections (2 × 10⁶), with either monalizumab (50 μg) or an isotype control antibody (50 μg). B Representative BLIs of orthotopic TT150630 tumors from the following 4 groups: (i) NK-92MI and isotype, (ii)NK-92MI and MS-275, (iii) NK-92MI and monalizumab and (iv) NK-92MI, MS-275 and monalizumab groups (n = 5/group). C Quantification of the BLI signal in (B). D Kaplan‒Meier survival curves for mice xenografted with TT150630-luciferase cells from each group are shown in (I) (n = 5/group). P values were calculated via the log-rank test.